Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 3
1956 9
1957 10
1958 9
1959 8
1960 9
1961 7
1962 8
1963 22
1964 34
1965 21
1966 18
1967 33
1968 34
1969 31
1970 34
1971 40
1972 42
1973 36
1974 43
1975 32
1976 32
1977 44
1978 55
1979 69
1980 92
1981 125
1982 123
1983 128
1984 179
1985 202
1986 215
1987 250
1988 241
1989 276
1990 305
1991 307
1992 349
1993 367
1994 367
1995 441
1996 511
1997 550
1998 613
1999 724
2000 736
2001 748
2002 733
2003 780
2004 820
2005 876
2006 973
2007 1001
2008 1100
2009 1124
2010 1208
2011 1236
2012 1447
2013 1614
2014 1706
2015 1628
2016 1741
2017 1827
2018 1904
2019 1967
2020 2241
2021 1370
Text availability
Article attribute
Article type
Publication date

Search Results

33,060 results
Results by year
Filters applied: . Clear all
Page 1
Optimizing the Clinical Use of Vancomycin.
Álvarez R, López Cortés LE, Molina J, Cisneros JM, Pachón J. Álvarez R, et al. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2601-9. doi: 10.1128/AAC.03147-14. Print 2016 May. Antimicrob Agents Chemother. 2016. PMID: 26856841 Free PMC article. Review.
Nephrotoxicity has been associated with target vancomycin trough levels above 15 mg/liter. Continuous infusion is an option, especially for patients at high risk of renal impairment or unstable vancomycin clearance. In such cases, vancomycin plasma steady-sta …
Nephrotoxicity has been associated with target vancomycin trough levels above 15 mg/liter. Continuous infusion is an option, especial …
The pharmacokinetic and pharmacodynamic properties of vancomycin.
Rybak MJ. Rybak MJ. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. doi: 10.1086/491712. Clin Infect Dis. 2006. PMID: 16323118 Review.
Therefore, understanding the clinical implications of the pharmacokinetic and pharmacodynamic properties of vancomycin is a necessity for clinicians. Vancomycin is a concentration-independent antibiotic (also referred to as a "time-dependent" antibiotic), and there …
Therefore, understanding the clinical implications of the pharmacokinetic and pharmacodynamic properties of vancomycin is a necessity …
Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria.
Mühlberg E, Umstätter F, Kleist C, Domhan C, Mier W, Uhl P. Mühlberg E, et al. Can J Microbiol. 2020 Jan;66(1):11-16. doi: 10.1139/cjm-2019-0309. Epub 2019 Sep 23. Can J Microbiol. 2020. PMID: 31545906 Free article. Review.
Since the discovery of the first vancomycin-resistant enterococci strains in the late 1980s, the number of resistances has been steadily rising, with often life-threatening consequences. As an alternative to the generation of completely new substances, novel approaches foc …
Since the discovery of the first vancomycin-resistant enterococci strains in the late 1980s, the number of resistances has been stead …
Vancomycin.
Wilhelm MP. Wilhelm MP. Mayo Clin Proc. 1991 Nov;66(11):1165-70. doi: 10.1016/s0025-6196(12)65799-1. Mayo Clin Proc. 1991. PMID: 1943250 Review.
Vancomycin is bactericidal against most strains of staphylococci and nonenterococcal streptococci. Although rare strains of staphylococci and enterococci that are resistant to vancomycin have been reported, bacterial resistance has thus far not emerged as a major cl
Vancomycin is bactericidal against most strains of staphylococci and nonenterococcal streptococci. Although rare strains of staphyloc
Vancomycin: a history.
Levine DP. Levine DP. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12. doi: 10.1086/491709. Clin Infect Dis. 2006. PMID: 16323120
In addition, resistance to vancomycin developed, first in enterococci and later in staphylococci. ...The findings of future studies may result in a return to measuring levels of vancomycin in serum, to assure a successful therapeutic outcome....
In addition, resistance to vancomycin developed, first in enterococci and later in staphylococci. ...The findings of future studies m …
Does oral vancomycin use necessitate therapeutic drug monitoring?
Cimolai N. Cimolai N. Infection. 2020 Apr;48(2):173-182. doi: 10.1007/s15010-019-01374-7. Epub 2019 Nov 11. Infection. 2020. PMID: 31713055 Review.
This review examines the cumulative scientific evidence that guides therapeutic monitoring of oral vancomycin therapy. METHODS: The existing publications were reviewed from the time of the drug's inception to July 2019. ...CONCLUSION: Until systemic toxicity from or …
This review examines the cumulative scientific evidence that guides therapeutic monitoring of oral vancomycin therapy. METHODS: The e …
Vancomycin loading doses: a systematic review.
Reardon J, Lau TT, Ensom MH. Reardon J, et al. Ann Pharmacother. 2015 May;49(5):557-65. doi: 10.1177/1060028015571163. Epub 2015 Feb 23. Ann Pharmacother. 2015. PMID: 25712445 Review.
Nonhuman, non-English, oral vancomycin, and dialysis patient studies were excluded. Abstracts were included. ...Limitations included heterogeneity and inconsistent timing of concentration measurements. CONCLUSIONS: High-quality data to guide the use of vancomycin LD …
Nonhuman, non-English, oral vancomycin, and dialysis patient studies were excluded. Abstracts were included. ...Limitations included …
A Moving Target-Vancomycin Therapeutic Monitoring.
Burns AN, Goldman JL. Burns AN, et al. J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):474-478. doi: 10.1093/jpids/piaa078. J Pediatric Infect Dis Soc. 2020. PMID: 32716487 Review.
Therapeutic drug monitoring (TDM) has been a common practice to optimize efficacy and safety of vancomycin. While vancomycin trough-only TDM has widely been integrated into pediatric clinical practice since 2009, recently updated vancomycin TDM guidelines pub …
Therapeutic drug monitoring (TDM) has been a common practice to optimize efficacy and safety of vancomycin. While vancomycin t …
Vancomycin.
Cunha BA. Cunha BA. Med Clin North Am. 1995 Jul;79(4):817-31. doi: 10.1016/s0025-7125(16)30041-4. Med Clin North Am. 1995. PMID: 7791425 Review.
Vancomycin should not be added to drug regimens for gram-positive coverage, and the empiric use of vancomycin should be discouraged to avoid the emergence of VRE. Vancomycin serum levels are no longer necessary or cost effective in most patients because va
Vancomycin should not be added to drug regimens for gram-positive coverage, and the empiric use of vancomycin should be discou
Vancomycin: The pendulum swings.
Scheetz MH. Scheetz MH. Am J Health Syst Pharm. 2020 May 19;77(11):810-811. doi: 10.1093/ajhp/zxaa076. Am J Health Syst Pharm. 2020. PMID: 32426842 No abstract available.
33,060 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page